Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Study Overview
=================
Brief Summary
-----------------
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.

Official Title
-----------------
A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Anagliptin
* Drug: Sitagliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had diagnosed with type 2 DM before 3 months Men and women between the age of ≥ 19 and ≤ 75 years FPG ≤ 270 mg/dL at screening visit Patients who consent to participate in this trial by written Informed Consent Form Exclusion Criteria: Type 1 DM or secondary diabetes Subjects who are administrating oral anti-hyperglycemic drugs or have to take a medicine Body mass index < 20 kg/m2 or > 40.0kg/m2 Subjects who are assessed to be inappropriate for this trial by investigator

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sitagliptin<br>Sitagliptin 100mg | Drug: Sitagliptin<br>* Sitagliptin 100mg, tablet, once a day (QD)<br>|
| Experimental: CWP-0403<br>CWP-0403 100mg | Drug: Anagliptin<br>* Anagliptin 100mg, tablet, twice a day (BID)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Change in HbA1c from baseline to week24. |  | 0wk, 8wk, 16wk, 24wk | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of subjects achieving HbA1c<7% at week24 |  | 0wk, 8wk, 16wk, 24wk | 
| The proportion of subjects achieving HbA1c<6.5% at week24 |  | 0wk, 8wk, 16wk, 24wk | 
| The change from baseline to week 24: Fasting plasma glucose |  | 0wk, 24wk | 
| change from baseline to week 24: Fasting serum insulin |  | 0wk, 24 wk | 
| change from baseline to week 24 in Fasting serum pro-insulin |  | 0wk, 24wk | 
| change from baseline to week 24 in Fasting serum c-peptide |  | 0wk, 24wk | 
| change from baseline to week 24 in HOMA-β |  | 0wk, 24 wk | 
| change from baseline to week 24 in HOMA-IR |  | 0wk, 24 wk | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CWP-0403, Sitagliptin, Metformin, type 2 DM